Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background Episodes of depression are the most frequent cause of disability among patients with bipolar disorder. The effectiveness and safety of standard antidepressant agents for depressive episodes associated with bipolar disorder (bipolar depression) have not been well studied. Our study was designed to determine whether adjunctive antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania. Methods In this double-blind, placebo-controlled study, we randomly assigned subjects with bipolar depression to receive up to 26 weeks of treatment with a mood stabilizer plus adjunctive antidepressant therapy or a mood stabilizer plus a matching placebo, under conditions generalizable to routine clinical care. A standardized clinical monitoring form adapted from the mood-disorder modules of the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, was used at all follow-up visits. The primary outcome was the percentage of subjects in each treatment group meeting the criterion for a durable recovery (8 consecutive weeks of euthymia). Secondary effectiveness outcomes and rates of treatment-emergent affective switch (a switch to mania or hypomania early in the course of treatment) were also examined. Results Forty-two of the 179 subjects (23.5%) receiving a mood stabilizer plus adjunctive antidepressant therapy had a durable recovery, as did 51 of the 187 subjects (27.3%) receiving a mood stab…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on negative placebo‐controlled data, we do not recommend paroxetine (level 2 negative).245”
In the citing paper
“Antimanic medications reduce depressive symptoms in only one-third of patients (2).”
From Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial (2018) · cites this paper as [2]
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Prevalence and Treatment of Mental Disorders, 1990 to 2003
Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., Wang, P., Wells, K. B., & Zaslavsky, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa043266 · Cited by 1,910
Extending Indications for Long-Term Pharmacotherapy: Opportunities and Challenges
Kane, J. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.1 · Cited by 987
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Self-citationPerlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689
Self-citationPrevalence and Treatment of Mental Disorders
(2005) · New England Journal of Medicine · doi:10.1056/nejmc051936 · Cited by 650
Research works printed but not linked: 4
- Murray CJ, 1994, Bull World Health Organ, 72, 495
- Sheehan DV, 1998, J Clin Psychiatry, 59, 22
- Sachs GS, 1994, J Clin Psychiatry, 55, 391
- 10.1037/0021-843X.108.4.579 · doi:10.1037/0021-843x.108.4.579 · Paper page
Cited by
Items 101–200 of 935
Ultra‐brief pulse ECT in bipolar and unipolar depressive disorder: differences in speed of response
Sienaert, P., Vansteelandt, K., Demyttenaere, K., & Peuskens, J. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00702.x · Cited by 98
Magalhães, P. V., Dodd, S., Nierenberg, A. A., & Berk, M. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412460593 · Cited by 99
“Patients in STEP-BD could be included in the randomized pathway if they fulfilled DSM-IV criteria for major Australian & New Zealand Journal of Psychiatry, 46(11) depression during the study (Sachs et al., 2003, 2007).”
BackgroundMethodSelf-citationTavares, D. F., Myczkowski, M. L., Alberto, R. L., Valiengo, L. D. C. L., Rios, R. M., Gordon, P. C., Sampaio-Júnior, B., Klein, I., Mansur, C. G., Marcolin, M. A., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.26 · Cited by 101
“Furthermore, antidepressant drugs (ADs), for example, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants and others, which are the main treatment for unipolar depression, have limited efficacy and adverse effects in BD (Sachs et al, 2007).”
BackgroundThe Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update
Bobo, W. V. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.06.022 · Cited by 118
Sartorius, N., Baghai, T. C., Baldwin, D. S., Barrett, B., Brand, U., Fleischhacker, W., Goodwin, G., Grunze, H., Knapp, M., Leonard, B. E., et al. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008255 · Cited by 98
“Moreover the use of adjunctive antidepressant medication in was not associated in with increased efficacy in comparison to treatment with mood stabilizers alone (Sachs et al., 2007).”
ResultRapid Mood-Elevating Effects of Low Field Magnetic Stimulation in Depression
Rohan, M. L., Yamamoto, R. T., Ravichandran, C. T., Cayetano, K. R., Morales, O. G., Olson, D. P., Vitaliano, G., Paul, S. M., & Cohen, B. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.024 · Cited by 97
“However, it is the depression that is the primary cause of disability and death in both these disorders (5).”
A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression
Brown, E. S., Park, J., Marx, C. E., Hynan, L. S., Gardner, C., Davila, D., Nakamura, A., Sunderajan, P., Lo, A., & Holmes, T. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.138 · Cited by 96
“Some traditional antidepressants may be ineffective for bipolar depression (Sachs et al, 2007) and perhaps detrimental to long-term mood stability (Daray et al, 2010; El-Mallakh et al, 2008; Ghaemi et al, 2010; Pacchiarotti et al, 2013; Post et al, 2012).”
BackgroundPharmacological Management of Bipolar Depression: Acute Treatment, Maintenance, and Prophylaxis
Vieta, E., & Valentí, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0073-y · Cited by 104
“Thus, this study does not support the usefulness of adjunctive antidepressant therapy [43], and it is in accord with earlier reports [44].”
ResultInterpretable Dynamic Treatment Regimes
Zhang, Y., Laber, E. B., Davidian, M., & Tsiatis, A. A. (2017) · Journal of the American Statistical Association · doi:10.1080/01621459.2017.1345743 · Cited by 128
“…an antidepressant medication to all patients did not lead to a better mean outcome relative to not applying antidepressants to any of the patients (Sachs et al., 2007), the estimated regime indicates that personalizing the use of antidepressants based on SUM-D may improve the overall mean outcome.”
BackgroundResultInfluentialPrioritizing Future Research on Off‐Label Prescribing: Results of a Quantitative Evaluation
Walton, S. M., Schumock, G. T., Lee, K., Alexander, G. C., Meltzer, D., & Stafford, R. S. (2008) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.12.1443 · Cited by 96
“Even as an adjunct to other therapies in depressive episodes, antidepressants do not appear to be effective for bipoplar disorder.(24) Hence, we view these drugs as valuable focal points for future research.”
BackgroundDe Fruyt, J., Deschepper, E., Audenaert, K., Constant, E., Floris, M., Pitchot, W., Sienaert, P., Souery, D., & Claes, S. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111408461 · Cited by 95
Overview of antidepressant treatment of bipolar depression
Vázquez, G. H., Tondo, L., Undurraga, J., & Baldessarini, R. J. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000023 · Cited by 94
“…diagnosed with unipolar depression (Ghaemi et al., 2003 ; Post et al., 2003b; Sharma et al., 2005 ; Calabrese et al., 2006; Goldberg et al., 2007 ; Sachs et al., 2007 ; O’Donovan et al., 2008 ; Phelps et al., 2008 ; Frye et al., 2009 ; Baldessarini et al., 2010d; Correa et al., 2010 ; Angst et…”
BackgroundInfluentialGlutamatergic Modulators in Depression
Henter, I. D., de Sousa, R. T., & Zarate, C. A. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000183 · Cited by 92
Loo, C. K. A., Katalinic, N., Mitchell, P. B., & Greenberg, B. D. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.08.017 · Cited by 103
“This concern has been particularly marked for the acute treatment of bipolar depressive episodes, with a major trial demonstrating no apparent benefit of antidepressants (Sachs et al., 2007), and a recent naturalistic longitudinal prospective study (Solomon et al.”
BackgroundRive, M. M., Mocking, R. J. T., Koeter, M. W. J., van Wingen, G., de Wit, S. J., van den Heuvel, O. A., Veltman, D. J., Ruhé, H. G., & Schene, A. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0161 · Cited by 89
Coplan, J. D., Gopinath, S., Abdallah, C. G., & Berry, B. R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00189 · Cited by 90
Sihvo, S., Isometsä, E. T., Kiviruusu, O. H., Hämäläinen, J., Suvisaari, J., Perälä, J., Pirkola, S. P., Saarni, S. I., & Lönnqvist, J. K. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.01.012 · Cited by 106
Revitalizing Psychiatric Therapeutics
Hyman, S. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.181 · Cited by 98
“Many patients with depression (most notably bipolar depression) and anxiety disorders have substantial residual symptoms despite optimal use of current treatments (Rush et al, 2006; Sachs et al, 2007).”
BackgroundImpact of living with bipolar patients: Making sense of caregivers’ burden
Pompili, M., Harnic, D., Gonda, X., Forte, A. M., Dominici, G., Innamorati, M., Fountoulakis, K. Ν., Serafini, G., Sher, L., Janiri, L., et al. (2014) · World Journal of Psychiatry · doi:10.5498/wjp.v4.i1.1 · Cited by 102
Treatment of bipolar depression: An update
Fountoulakis, K. Ν., Grunze, H., Panagiotidis, P., & Kaprinis, G. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.10.016 · Cited by 93
Transition to Mania During Treatment of Bipolar Depression
Perlis, R. H., Ostacher, M. J., Goldberg, J. F., Miklowitz, D. J., Friedman, E. S., Calabrese, J. R., Thase, M. E., & Sachs, G. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.122 · Cited by 89
Self-citationIs unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression?
Correa, R., Akiskal, H. S., Gilmer, W. S., Nierenberg, A. A., Trivedi, M. H., & Zisook, S. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.036 · Cited by 101
“TCAs and venlafaxine are reported as the drugs with the highest risk of switch into sustained mania or rapid cycling and SSRIs and MAOIs as the safest antidepressants in this regard (Akiskal, 1983; Young, 2000; Nemeroff et al., 2001; Sachs et al., 2007).”
BackgroundResultSelf-citationDell’Osso, B. M., Cafaro, R., & Ketter, T. A. (2021) · International Journal of Bipolar Disorders · doi:10.1186/s40345-020-00207-z · Cited by 102
Self-citationBrennan, B. P., Jensen, J. E., Hudson, J. I., Coit, C. E., Beaulieu, A., Pope, H. G., Renshaw, P. F., & Cohen, B. M. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31829a83f5 · Cited by 82
“Furthermore, traditional monoaminergic antidepressant agents may not outperform mood stabilizers alone in such patients.(5) Thus, novel treatment strategies for bipolar depression are needed.”
Rubin-Falcone, H., Zanderigo, F., Thapa-Chhetry, B., Lan, M., Miller, J. M., Sublette, M. E., Oquendo, M. A., Hellerstein, D. J., McGrath, P. J., Stewart, J. W., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.043 · Cited by 81
“Some data suggest that usual antidepressants also may not be as effective at treating the bipolar depression (Sachs et al., 2007).”
BackgroundAntidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients
El‐Mallakh, R. S., Ghaemi, S. N., Sagduyu, K., Thase, M. E., Wisniewski, S. R., Nierenberg, A. A., Zhang, H. W., Pardo, T. A., & Sachs, G. S. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.025 · Cited by 85
Self-citationModelling mood disorders: An ACE solution?
Malhi, G. S., Irwin, L., Hamilton, A., Morris, G., Boyce, P., Mulder, R., & Porter, R. J. (2018) · Bipolar Disorders · doi:10.1111/bdi.12700 · Cited by 79
Bipolar disorder and suicide: Research synthesis and clinical translation
McIntyre, R. S., Muzina, D. J., Kemp, D. E., Blank, D., Woldeyohannes, H. O., Lofchy, J., Soczynska, J. K., Banik, S., & Konarski, J. Z. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0012-7 · Cited by 91
“No antidepressant agent has an established safety and efficacy record (ie, replicated, adequately powered registration trials) in any phase of BD. In the largest effectiveness study to assess adjunctive unimodal antidepressants’ role in BD, neither paroxetine nor bupropion provided an advantage over placebo in achievi…”
BackgroundEarly intervention in bipolar disorders: Clinical, biochemical and neuroimaging imperatives
Berk, M., Malhi, G. S., Hallam, K., Gama, C. S., Dodd, S., Andreazza, A. C., Frey, B. N., & Kapczinski, F. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.08.011 · Cited by 84
Altshuler, L. L., Post, R. M., Hellemann, G., Leverich, G. S., Nolen, W. A., Frye, M. A., Keck, P. E., Kupka, R. W., Grunze, H., McElroy, S. L., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04191 · Cited by 81
“Patients were included in the acute trial if they (1) met DSM-IV(26) criteria for bipolar depressed phase despite adequate treatment with a mood stabilizer, (2) had an Inventory for Depressive Symptomatology (IDS)(27) score of at least 16, and (3) had a Clinical Global Impressions Scale for Bipolar Disorder (CGI-BP)(2…”
BackgroundMethodInfluentialChildhood trauma and treatment outcome in bipolar disorder
Cakir, S., Tasdelen Durak, R., Ozyildirim, I., Ince, E., & Sar, V. (2016) · Journal of Trauma & Dissociation · doi:10.1080/15299732.2015.1132489 · Cited by 80
“The efficacy of antidepressant treatment is known to be limited in BP (Ghaemi, Wingo, Filkowski, & Baldessarini, 2008; Sachs et al., 2007).”
BackgroundMartinotti, G., Dell’Osso, B. M., Lorenzo, G. D., Maina, G., Bertolino, A., Clerici, M., Barlati, S., Rosso, G., Nicola, M. D., Marcatili, M., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13296 · Cited by 93
Patterns of pharmacotherapy for bipolar disorder: A GBC survey
Singh, B., Yocum, A. K., Strawbridge, R., Burdick, K. E., Millett, C. E., Peters, A. T., Sperry, S. H., Fico, G., Vieta, E., Verdolini, N., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13366 · Cited by 84
“10 19– 22 Despite higher rates of anxiety disorders, there was no significant difference in ADs or benzodiazepine prescription rates geographically in BD-II.”
BackgroundSelf-citationTondo, L., Baldessarini, R. J., Vázquez, G., Lepri, B., & Visioli, C. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12023 · Cited by 79
Nusslock, R., Young, C. B., & Damme, K. S. F. (2014) · Behaviour Research and Therapy · doi:10.1016/j.brat.2014.08.011 · Cited by 76
“Buproprion, which inhibits catecholamine transporters including dopamine, is an effective treatment for bipolar depression (Post et al., 2006; Sachs et al., 2007).”
BackgroundPharmacotherapy of Mood Disorders
Thase, M. E., & Denko, T. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.2.022305.095301 · Cited by 79
Self-citationYatham, L. N., Vieta, E., Goodwin, G. M., Bourin, M., de Bodinat, C., Laredo, J., & Calabrese, J. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.147587 · Cited by 79
Self-citationBipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients
Valentí, M., Pacchiarotti, I., Rosa, A. R., Bonnín, C. M., Popovic, D., Nivoli, A. M. A., Murru, A., Grande, Í., Colom, F., & Vieta, E. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00908.x · Cited by 78
Yoon, S. J., Lyoo, I. K., Haws, C. A., Kim, T. S., Cohen, B. M., & Renshaw, P. F. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.2 · Cited by 81
Advances toward precision medicine for bipolar disorder: mechanisms & molecules
Haggarty, S. J., Karmacharya, R., & Perlis, R. H. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0831-4 · Cited by 78
“depressants have repeatedly failed to show benefit in randomized, placebo-controlled trials [13, 14].”
BackgroundTreatment of bipolar disorder: a complex treatment for a multi-faceted disorder
Fountoulakis, K. N., Vieta, E., Siamouli, M., Valenti, M., Magiria, S., Oral, T., Fresno, D., Giannakopoulos, P., & Kaprinis, G. S. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-27 · Cited by 76
“some authors that the true rate of switching is rather low, if any [154,156-158].”
Lara, D. R., Bisol, L. W., Brunstein, M. G., Reppold, C. T., de Carvalho, H. W., & Ottoni, G. L. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.036 · Cited by 87
““unipolar” depression comorbid with bipolar disorder, unlike the “natural” depressive episode of bipolar disorder that responds poorly to antidepressants) (Sachs et al., 2007).”
BackgroundDiscriminating Between Bipolar Disorder and Major Depressive Disorder
Vöhringer, P. A., & Perlis, R. H. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.10.001 · Cited by 74
Lombardo, I., Sachs, G., Kolluri, S., Kremer, C., & Yang, R. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825ccde5 · Cited by 75
“(2) Analysis comparing the actual and predicted (ie, derived from HAM-D-17)MADRS total scores at both baseline and the end of the study (usingLOCFdata)were performed as ameasure of rating reliability.”
BackgroundSelf-citationAims and Results of the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP‐BD)
Bowden, C. L., Perlis, R. H., Thase, M. E., Ketter, T. A., Ostacher, M. J., Calabrese, J. R., Reilly-Harrington, N. A., Gonzalez, J. M., Singh, V. K., Nierenberg, A. A., et al. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00257.x · Cited by 76
“Of the 22 centers engaged for the STEP-BD, 13 enrolled 90% of the total and six contributed two thirds of patients [2–4].”
BackgroundSelf-citationTreatment‐resistant bipolar depression: towards a new definition
Pacchiarotti, I., Mazzarini, L., Colom, F., Sanchez‐Moreno, J., Girardi, P., Kotzalidis, G. D., & Vieta, E. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01471.x · Cited by 74
“In the largest field study that tested the effectiveness of the addition of paroxetine or bupropion on standard care, the STEP-BD (36), it was suggested that standard antidepressant medications (paroxetine and bupropion) added to traditional mood stabilizers (lithium, valproate, carbamazepine or other FDA-approved ant…”
BackgroundResultInfluentialLiu, B., Zhang, Y., Fang, H., Liu, J., Liu, T., & Li, L. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.07.023 · Cited by 82
“…(Altshuler et al., 2003; Viktorin et al., 2014), study protocol (Simpson et al., 2009), no data reported about the acute responders or remitters (Sachs et al., 2007; Leverich et al., 2006), reanalysis of data from other studies (Amsterdam et al., 2013; Vohringer et al., 2015; Altshuler et al.,…”
ResultElectroconvulsive Therapy in Mania: A Review of 80 Years of Clinical Experience
Elias, A., Thomas, N., & Sackeïm, H. A. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20030238 · Cited by 77
Haro, J. M., Reed, C. C., González-Pinto, A. M., Novick, D., Bertsch, J., & Vieta, E. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.08.001 · Cited by 84
“The association of antidepressant use with outcome is still a matter of debate, since some reports find an association with a poor outcome (Ghaemi et al., 2000; Bauer et al., 2005), while others fail to find any association (Sachs et al., 2007; Goldstein et al., 1999).”
Dias, R. S., Lafer, B., Russo, C., Del Debbio, A., Nierenberg, A. A., Sachs, G. S., & Joffe, H. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09121816 · Cited by 70
“These agents are highly effective in the treatment of premenstrual dysphoric disorder (15), and although their role in treating premenstrual exacerbation symptoms in women with bipolar disorder remains unclear (11, 12, 23), it is possible that the more widespread use of SSRIs and SNRIs in recent years protected women…”
BackgroundSelf-citationSleep, illness course, and concurrent symptoms in inter-episode bipolar disorder
Eidelman, P., Talbot, L. S., Gruber, J., & Harvey, A. G. (2010) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2009.11.007 · Cited by 68
Medda, P., Perugi, G., Zanello, S., Ciuffa, M., Rizzato, S., & Cassano, G. B. (2010) · The Journal of ECT · doi:10.1097/yct.0b013e3181b00f1e · Cited by 70
“A recent study indicates that antidepressant add-on in bipolar depression is no more efficacious than optimized mood stabilizer monotherapy.(1) Moreover, treatment with antidepressants has been linked with manic switches, mixed state (MS) induction, and cycle acceleration.”
BackgroundThe primacy of mania: A reconsideration of mood disorders
Koukopoulos, A., & Ghaemi, S. N. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.07.006 · Cited by 82
“[116] Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al.”
BackgroundInvestigating the mechanism(s) underlying switching between states in bipolar disorder
Young, J. W., & Dulcis, D. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.019 · Cited by 68
“Treatment with bupropion – a combined dopamine/norepinephrine reuptake inhibitor – also induces switches in rates up to 19% (Sachs et al., 2007), although many studies focused on its use as an adjunctive therapy to mood stabilizing treatment (Salvadore et al., 2010).”
BackgroundGuideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012
Kanba, S., Kato, T., Terao, T., Yamada, K., & Committee for Treatment Guidelines of Mood Disorders, J. S. O. M. D. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12060 · Cited by 68
“According to the results of a large RCT (the STEP-BD study), combination therapy with a mood stabilizer and an antidepressant (paroxetine or bupropion) was not superior to treatment with a mood stabilizer alone, although the risk of a manic switch requiring emergency treatment did not differ.(34) According to the resu…”
ResultChallenges in the diagnosis and treatment of pediatric bipolar depression
Chang, K. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.1/kchang · Cited by 66
Evidence-Based Psychotherapies for Bipolar Disorder
Novick, D. M., & Swartz, H. A. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20190004 · Cited by 83
“Although the utility of adding antidepressant medication to a mood stabilizer for the management of bipolar depression remains a controversial strategy (95, 96), adding psychotherapy is clearly bene fi cial and well supported by the evidence.”
Jann, M. W. (2014) · PubMed · Cited by 97
Medication burden in bipolar disorder: A chart review of patients at psychiatric hospital admission
Weinstock, L. M., Gaudiano, B. A., Epstein-Lubow, G., Tezanos, K., Celis-deHoyos, C. E., & Miller, I. W. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.01.038 · Cited by 65
“, antidepressant, benzodiazepine, stimulant) medications with mixed efficacy support (Yatham et al., 2005; Sachs et al., 2007; McIntyre, 2009) for the treatment of BD.”
BackgroundFateh, A. A., Long, Z., Duan, X., Cui, Q., Pang, Y., Farooq, M. U., Nan, X., Chen, Y., Sheng, W., Tang, Q., et al. (2019) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2019.01.004 · Cited by 63
Psychotherapy as monotherapy for the treatment of bipolar II depression: a proof of concept study
Swartz, H. A., Frank, E., Frankel, D. R., Novick, D., & Houck, P. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00629.x · Cited by 63
Epigenetic mechanisms in mood disorders: Targeting neuroplasticity
Fass, D. M., Schroeder, F. A., Perlis, R. H., & Haggarty, S. J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2013.01.041 · Cited by 62
“Specifically, standard antidepressants have repeatedly failed to show benefit in randomized, controlled trials (Nemeroff et al., 2001, Sachs et al., 2007).”
Backgroundvan der Loos, M. L., Mulder, P., Hartong, E. G., Blom, M. B., Vergouwen, A. C., van Noorden, M. S., Timmermans, M. A., Vieta, E., Nolen, W. A., & for the LamLit Study Group* (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00887.x · Cited by 61
“There is a controversy regarding the use of antidepressants, both in the treatment of acute depressive episodes (9, 10) as well as in long-term treatment of bipolar disorder (11–13).”
BackgroundKemp, D. E., Ganocy, S. J., Brecher, M., Carlson, B. X., Edwards, S., Eudicone, J. M., Evoniuk, G., Jansen, W., Leon, A. C., Minkwitz, M., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.10.026 · Cited by 62
“For instance, though standard antidepressants have proven to be efficacious in treating unipolar depression, their efficacy in bipolar depression is inconclusive, with one large, randomized, placebo-controlledeffectiveness studyfindingantidepressants to confer no additional benefit when added to a mood stabilizer comp…”
BackgroundSelf-citationPharmacotherapy for the Treatment of Acute Bipolar II Depression: Current Evidence
Swartz, H. A., & Thase, M. E. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05192gre · Cited by 60
Self-citationGrunze, H. C. R. (2008) · CNS Spectrums · doi:10.1017/s1092852900013912 · Cited by 61
“The autors stated "The pharmacotherapy procedures were based on expert consensus guidelines, such as those published by American Psychiatric Association and others.(6) The treatment choices were presented in tiers, corresponding to treatments considered 'first line' in one or more published guidelines, 'second line,'…”
InfluentialHigh-dose prazosin for the treatment of post-traumatic stress disorder
Koola, M. M., Varghese, S. P., & Fawcett, J. A. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313500982 · Cited by 58
“Mirtazapine and sertraline were tapered and discontinued because of the new bipolar II diagnosis [Sachs et al. 2007; Salvi et al. 2008; Alda and Yatham, 2009] and diazepam was tapered and discontinued as the patient had PTSD which was symptomatic [Asnis et al. 2004; Lund et al. 2012].”
BackgroundTreatment of Rapid-Cycling Bipolar Disorder: Are Antidepressants Mood Destabilizers?
Ghaemi, S. N. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07121931 · Cited by 66
“Although some agents may have low rates of acute manic switch (8), especially when used with mood stabilizers (9), the data from STEP-BD suggest that even the new generation of antidepressants can produce long-term mood destabilization.”
Amsterdam, J. D., Lorenzo-Luaces, L., Soeller, I., Li, S. Q., Mao, J. J., & DeRubeis, R. J. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.05.070 · Cited by 57
“…Shults, 2010a, b; Kupfer et al., 2001), other studies have not confirmed this finding or have reported increased mood conversion rates during continuation antidepressant use (Altshuler et al., 1995; Ghaemi et al., 2004; Leverich et al., 2006; Sachs et al., 2007; Vieta, 2008; Viktorin et al., 2014).”
BackgroundResultAn update on antidepressant use in bipolar depression
Sidor, M. M., & MacQueen, G. M. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0323-6 · Cited by 57
“Antidepressants considered in these trials were paroxetine [8], fluoxetine [38, 39], sertraline [35], bupropion [8, 35], venlaflaxine [35, 40] and citalopram [41].”
InfluentialCorticosteroid-Induced Psychiatric Disorders: Mechanisms, Outcomes, and Clinical Implications
Nasereddin, L., Alnajjar, O., Bashar, H., Abuarab, S. F., Al-Adwan, R., Chellappan, D. K., & Barakat, M. M. (2024) · Diseases · doi:10.3390/diseases12120300 · Cited by 67
Greil, W., Häberle, A., Haueis, P., Grohmann, R., & Russmann, S. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.033 · Cited by 63
The course of bipolar disorder
Saunders, K. E. A., & Goodwin, G. M. (2010) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.107.004903 · Cited by 56
Bipolar depression: Clinical correlates of receiving antidepressants
Undurraga, J. P., Baldessarini, R. J., Valentí, M., Pacchiarotti, I., Tondo, L., Vázquez, G. H., & Vieta, E. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.027 · Cited by 57
“, 2003) and three did not (Nemeroff et al., 2001; Sachs et al., 2007; McElroy et al., 2010).”
Amsterdam, J. D., & Shults, J. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181da5300 · Cited by 56
“A subsequent, double-blind study examined the efficacy and mood conversion rate of bupropion or paroxetine therapy (n = 179) versus placebo (n = 187) in a mixed population of bipolar I and II depressed patients on established mood stabilizer therapy.(22) Recovery rates were low during both antidepressant (23.”
BackgroundMethodResultVan Lieshout, R. J., & MacQueen, G. M. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.057612 · Cited by 57
Tamayo, J. M., Zarate, C. A., Vieta, E., Vázquez, G. H., & Tohen, M. F. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709991246 · Cited by 57
“For bipolar depressed patients, there is uncertainty about the role of antidepressants as they have been associated with manic relapse (Lewis & Winokur, 1982), lack of efficacy (Post et al. 2006 ; Sachs et al. 2007), and cycle acceleration (Wehr & Goodwin, 1979).”
BackgroundKoszewska, I., & Rybakowski, J. K. (2009) · Neuropsychobiology · doi:10.1159/000202824 · Cited by 56
“is that in the sample with severe BD switching from depression to mania was not associated with AD treatment. Nevertheless, the current guidelines recommend a restricted use of ADs in the treatment of bipolar depression. Furthermore, the clinical efficacy of ADs in bipolar depression has been questioned. In a recent s…”
ResultAmsterdam, J. D., Wang, C.-H., Shwarz, M., & Shults, J. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.029 · Cited by 57
“Another analysis from the same study found no specific benefit from antidepressant therapy (in combination with mood stabilizers) in BP depression and an increase in the frequency of mood conversion episodes versus mood stabilizer monotherapy (Sachs et al., 2007).”
BackgroundResultMedicating mood with maintenance in mind: bipolar depression pharmacotherapy
Malhi, G. S., Adams, D., & Berk, M. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00711.x · Cited by 58
Häberle, A., Greil, W., Russmann, S., & Grohmann, R. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-153 · Cited by 57
“Recent reviews and studies on the efficacy of antidepressants alone or in combination in the treatment of bipolar depression do not find stable effects for their efficacy [37-42].”
BackgroundAmsterdam, J. D., Lorenzo-Luaces, L., Soeller, I., Li, S. Q., Mao, J. J., & DeRubeis, R. J. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.169375 · Cited by 52
“24 A retrospective study of bipolar I and II depression found that 44% of patients with a history of prior mood conversions had at least one mood conversion during antidepressant therapy, and that adjunctive mood stabiliser therapy provided little protection against antidepressant-induced manic…”
Malhi, G. S., Adams, D., Cahill, C. M., Dodd, S., & Berk, M. (2009) · Drugs · doi:10.2165/11318850-000000000-00000 · Cited by 64
Receptor targets for antidepressant therapy in bipolar disorder: An overview
Fountoulakis, K. Ν., Kelsoe, J. R., & Akiskal, H. S. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.04.043 · Cited by 54
Impact of psychotropic drugs on suicide and suicidal behaviors
Yerevanian, B. I., & Choi, Y. M. (2013) · Bipolar Disorders · doi:10.1111/bdi.12098 · Cited by 51
“The addition of antidepressants may not have a significant impact in the treatment of bipolar depression (43).”
BackgroundTreatment-resistant depression: problematic illness or a problem in our approach?
Malhi, G. S., Das, P., Mannie, Z., & Irwin, L. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.246 · Cited by 53
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0259-6 · Cited by 54
“chronicity and treatment refractoriness does not support the usefulness of an adjunctive antidepressant therapy [383], while, on the contrary, another earlier one supported the usefulness of paroxetine as add-on therapy [475].”
ResultSTEP-BD and bipolar depression: What have we learned?
Thase, M. E. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0068-9 · Cited by 55
Self-citationEvaluation of Treatment in 35 Cases of Bipolar Suicide
Keks, N. A., Hill, C., Sundram, S., Graham, A., Bellingham, K., Dean, B., Opeskin, K., Dorissa, A., & Copolov, D. L. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670902873680 · Cited by 50
“Use of antidepressants remains controversial due to the possibility of affective switching and cycle acceleration, and lack of efficacy in controlled studies [15,16].”
BackgroundBobo, W. V., & Shelton, R. C. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.143 · Cited by 50
McClintock, S. M., Martin, D. M., Lisanby, S. H., Alonzo, A., McDonald, W. M., Aaronson, S. T., Husain, M. M., O’Reardon, J. P., Weickert, C. S., Mohan, A., et al. (2020) · Depression and Anxiety · doi:10.1002/da.22988 · Cited by 54
“…given limited response and remission rates and possible adverse treatment‐ associated side effects, the neuropsychiatric field is in need of more effective antidepressant therapies (Collins, Patel, Joestl, March, & Insel, 2011; McClintock et al., 2018; Rush et al., 2006; Sachs et al., 2007).”
BackgroundGoldberg, D. P., Andrews, G., & Hobbs, M. J. (2009) · Psychological Medicine · doi:10.1017/s0033291709990304 · Cited by 49
“Sachs et al. (2007) report a large prospective randomized control trial that compared the use of standard antidepressant medication plus mood stabilizers versus mood stabilizers plus placebo in patients with bipolar depression followed for up to 26 weeks.”
BackgroundTreatment options for acute depression in bipolar disorder
Bauer, M., Ritter, P., Grunze, H., & Pfennig, A. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2012.00991.x · Cited by 49
Kessing, L. V. (2024) · International Journal of Bipolar Disorders · doi:10.1186/s40345-023-00322-7 · Cited by 62
“Fourth, the STEP-BD study suggested that mood stabilizers which include lithium are as effective as mood stabilizers plus antide-pressants in treating acute bipolar depression (Sachs et al. 2007).”
BackgroundNicola, M. D., Risio, L. D., Pettorruso, M., Caselli, G., Crescenzo, F. D., Swierkosz-Lenart, K., Martinotti, G., Camardese, G., Giannantonio, M. D., & Janiri, L. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.023 · Cited by 53
“Bupropion is notably associated with low rates of switch to mania or hypomania and its short-term addition to mood-stabilizer therapy does not increase the risk of cycling (Sachs et al., 2007).”
BackgroundKasper, S. F., Calabrese, J. R., Johnson, G., Tajima, O., Vieta, E., Viguera, A. C., Yatham, L. N., & Young, A. H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1014 · Cited by 59
“Notably, the rate of treatmentemergent affective switch in the 2 groups was not significantly different.(54) Overall, adjunctive antidepressants may be effective in acute treatment of bipolar I or II depression, but they do not appear to provide any additional benefit in long-term treatment of bipolar depression.”
BackgroundMethodSelf-citationGao, K., Kemp, D. E., Ganocy, S. J., Muzina, D. J., Xia, G., Findling, R. L., & Calabrese, J. R. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00637.x · Cited by 49
Self-citationGold, A. K., Otto, M. W., Deckersbach, T., Sylvia, L. G., Nierenberg, A. A., & Kinrys, G. (2018) · American Journal on Addictions · doi:10.1111/ajad.12713 · Cited by 59
Self-citationBipolar depression and treatment with antidepressants
Goodwin, G. M. (2012) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.095349 · Cited by 50
Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
Yalın, N., & Young, A. H. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s245166 · Cited by 54
Metadata
- Authors
- Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., Ketter, T. A., Patel, J., Hauser, P., Rapport, D., Martinez, J. M., Allen, M. H., Miklowitz, D. J., Otto, M. W., Dennehy, E. B., & Thase, M. E.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- University Hospitals Cleveland Medical Center (US)
- Baylor College of Medicine (US)
- University of Pittsburgh (US)
- University of Pennsylvania (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Oklahoma (US)
- Stanford Medicine (US)
- University of Massachusetts Chan Medical School (US)
- University of Toledo (US)
- University of Colorado Boulder (US)
- Boston University (US)
- Purdue University West Lafayette (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-26
- Volume
- 356
- Issue
- 17
- Pages
- 1711-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166423384
- Semantic Scholar
- c224a40d0ffd6471e7b72b38060d169ba1cdec34
- Cited by
- 937
- References
- 27
- Citations by year
- 2026: 16 · 2025: 16 · 2024: 33 · 2023: 17 · 2022: 15 · 2021: 68 · 2020: 33 · 2019: 29 · 2018: 36 · 2017: 28 · 2016: 53 · 2015: 47 · 2014: 51 · 2013: 52 · 2012: 61
- FWCI
- 56.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh80001-12-0-0)
- National Institute of Mental Health (N01-MH80001)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- bipolar depression, adjunctive antidepressant therapy, mood stabilizers, euthymia, bipolar disorder, antidepressant safety
- MeSH terms
- Adult, Bipolar Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Bupropion, Treatment Outcome, Paroxetine, Antidepressive Agents, Second-Generation, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.